-
Something wrong with this record ?
Interaction of soy isoflavones and their main metabolites with hOATP2B1 transporter
L. Navrátilová, L. Applová, P. Horký, P. Mladěnka, P. Pávek, F. Trejtnar,
Language English Country Germany
Document type Journal Article
NLK
ProQuest Central
from 2013-01-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2000-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 2013-01-01 to 1 year ago
- MeSH
- Madin Darby Canine Kidney Cells MeSH
- Glycine max * MeSH
- Isoflavones pharmacology MeSH
- Kinetics MeSH
- Organic Anion Transporters antagonists & inhibitors genetics metabolism MeSH
- Dogs MeSH
- Transfection MeSH
- Animals MeSH
- Check Tag
- Dogs MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
Membrane organic anion-transporting polypeptides (OATPs) are responsible for the drug transmembrane transport within the human body. The function of OATP2B1 transporter can be inhibited by various natural compounds. Despite increased research interest in soya as a part of human diet, the effect of its active components to interact with hOATP2B1 has not been elucidated in a complex extent. This in vitro study examined the inhibitory effect of main soy isoflavones (daidzin, daidzein, genistin, genistein, glycitin, glycitein, biochanin A, formononetin) and their metabolites formed in vivo (S-equol, O-desmethylangolensin) towards human OATP2B1 transporter. MDCKII cells overexpressing hOATP2B1 were employed to determine quantitative inhibitory parameters of the tested compounds and to analyze mechanism/s of the inhibitory interaction. The study showed that aglycones of soy isoflavones and the main biologically active metabolite S-equol were able to significantly inhibit hOATP2B1-mediated transport. The Ki values for most of aglycones range from 1 to 20 μM. In contrast, glucosides did not exhibit significant inhibitory effect. The kinetic analysis did not indicate a uniform type of inhibition towards the hOATP2B1 although predominant mechanism of inhibition seemed to be competitive. These findings may suggest that tested soy isoflavones and their metabolites might affect transport of xenobiotics including drugs across tissue barriers via hOATP2B1.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19000623
- 003
- CZ-PrNML
- 005
- 20221018085349.0
- 007
- ta
- 008
- 190107s2018 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00210-018-1528-y $2 doi
- 035 __
- $a (PubMed)29934673
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Navrátilová, Lucie $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic.
- 245 10
- $a Interaction of soy isoflavones and their main metabolites with hOATP2B1 transporter / $c L. Navrátilová, L. Applová, P. Horký, P. Mladěnka, P. Pávek, F. Trejtnar,
- 520 9_
- $a Membrane organic anion-transporting polypeptides (OATPs) are responsible for the drug transmembrane transport within the human body. The function of OATP2B1 transporter can be inhibited by various natural compounds. Despite increased research interest in soya as a part of human diet, the effect of its active components to interact with hOATP2B1 has not been elucidated in a complex extent. This in vitro study examined the inhibitory effect of main soy isoflavones (daidzin, daidzein, genistin, genistein, glycitin, glycitein, biochanin A, formononetin) and their metabolites formed in vivo (S-equol, O-desmethylangolensin) towards human OATP2B1 transporter. MDCKII cells overexpressing hOATP2B1 were employed to determine quantitative inhibitory parameters of the tested compounds and to analyze mechanism/s of the inhibitory interaction. The study showed that aglycones of soy isoflavones and the main biologically active metabolite S-equol were able to significantly inhibit hOATP2B1-mediated transport. The Ki values for most of aglycones range from 1 to 20 μM. In contrast, glucosides did not exhibit significant inhibitory effect. The kinetic analysis did not indicate a uniform type of inhibition towards the hOATP2B1 although predominant mechanism of inhibition seemed to be competitive. These findings may suggest that tested soy isoflavones and their metabolites might affect transport of xenobiotics including drugs across tissue barriers via hOATP2B1.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a psi $7 D004285
- 650 _2
- $a isoflavony $x farmakologie $7 D007529
- 650 _2
- $a kinetika $7 D007700
- 650 _2
- $a buňky MDCK $7 D061985
- 650 _2
- $a přenašeče organických aniontů $x antagonisté a inhibitory $x genetika $x metabolismus $7 D027361
- 650 12
- $a Glycine max $7 D013025
- 650 _2
- $a transfekce $7 D014162
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Applová, Lenka $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic. $7 xx0277670
- 700 1_
- $a Horký, Pavel $u Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic.
- 700 1_
- $a Mladěnka, Přemysl $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic.
- 700 1_
- $a Pávek, Petr $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic.
- 700 1_
- $a Trejtnar, František $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic. trejtnarf@faf.cuni.cz.
- 773 0_
- $w MED00003462 $t Naunyn-Schmiedeberg's archives of pharmacology $x 1432-1912 $g Roč. 391, č. 10 (2018), s. 1063-1071
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29934673 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190107 $b ABA008
- 991 __
- $a 20221018085346 $b ABA008
- 999 __
- $a ok $b bmc $g 1364669 $s 1038746
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 391 $c 10 $d 1063-1071 $e 20180622 $i 1432-1912 $m Naunyn-Schmiedeberg's archives of pharmacology $n Naunyn Schmiedebergs Arch Pharmacol $x MED00003462
- LZP __
- $a Pubmed-20190107